The CureWorks collaborative model will be unconstrained by the status quo, which we believe will lead to more cures in less time, with less risk for all involved.
Our goal is to deliver effective and safe immunotherapies to patients earlier in their treatment cycle. Aggregating diverse data from trials will help us increase our overall understanding and accelerate our rate of progress. This approach maximizes the number of potential candidates to present for FDA review and approval and, ultimately, the therapies CureWorks is able to provide to our patients.
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD19+CD22+ Leukemia and Lymphoma | Seattle Children's, Children's National Hospital, BC Children's Hospital, Children's Hospital Los Angeles, Riley Hospital for Children | Active, Recruiting NCT03330691 |
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T Cell Immunotherapy for CD19+CD22+ Leukemia |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD22+ Leukemia and Lymphoma | Seattle Children's, Riley Hospital for Children, Children's National Hospital, Children's Hospital Los Angeles, Texas Children's Hospital | Active, recruiting, NCT04571138 |
Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study Of CD22-Specific CAR T Cells For CD22+ Leukemia Or Lymphoma |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD33 | Seattle Children's | Active, recruiting, NCT05105152 |
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study of SC-DARIC33 in Pediatric and Young Adults With Relapsed or Refractory CD33+ AML |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| EGFR+ (m806 epitope) Recurrent / Refractory solid tumors | Seattle Children's | Active NCT03618381 |
Phase 1 Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| B7H3+ Recurrent / Refractory solid tumors | Seattle Children's | Active NCT04483778 |
Phase 1 Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| Her2+ Recurrent/Refractory CNS tumors | Seattle Children's | Active NCT03500991 |
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| EGFR+ (m806 epitope) Recurrent / Refractory Central Nervous System (CNS) tumors | Seattle Children's | Active NCT03638167 |
Phase 1 Study Of EGFR806-Specific CAR T Cell Locoregionalimmunotherapy For EGFR-Positive Recurrent Or Refractory Pediatric Central Nervous System Tumors |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| B7H3+ Recurrent / Refractory Central Nervous System (CNS) tumors | Seattle Children's | Active NCT04185038 |
Phase 1 Study Of B7-H3-Specific CAR T Cell Locoregionalimmunotherapy For Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma And Recurrent Or Refractory Pediatric Central Nervous System Tumors |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| Recurrent/Refractory Osteosarcoma | Seattle Children's | Active NCT05312411 |
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma |